Redeye comments on Cereno’s Q3 2021 report following an eventful quarter. The FDA has recently approved Cereno’s IND application for its phase II trial with CS1 in PAH, putting the company on track for top-line data release in H2 2022. The company sits on a comfortable cash cushion, and we view clinical trial data as the primary catalyst for Cereno during the coming 12 months.

Länk till analysen